A JAK tyrosine kinase and pseudokinase Co-inhibition strategy combines enhanced potency and on-demand activation.
Chen X, Zhang L, Bao Q, Meng F, Liu C, Xu R, Ji X, You Q, Jiang Z.
Eur J Med Chem · journal article · DOI 10.1016/j.ejmech.2023.115198 PUBLIKATIONSREGISTRET
Gå till forskningen.
Publikationsdata från Europe PMC och PubMed. Följ källhänvisningar från ämnesregistret till originalpublikationerna.
Publikationer som ChEBI hänvisar till för decernotinib. Visa hela publikationsregistret
En publikationsträff är inte en slutsats. Publikationslistan visar bibliografiska uppgifter. Eventuella forskningsutdrag visas separat med originalunderlag. En källhänvisning visar inte i sig effekt, dosering eller säkerhet.
Publikationer i urvalet
8 träffarSynergistic effects of type I PRMT and PARP inhibitors against non-small cell lung cancer cells.
Dominici C, Sgarioto N, Yu Z, Sesma-Sanz L, Masson JY, Richard S, Raynal NJ.
Clin Epigenetics · research support, non-u.s. gov't; research-article; journal article · DOI 10.1186/s13148-021-01037-1Janus kinases (JAKs): The efficient therapeutic targets for autoimmune diseases and myeloproliferative disorders.
Xu P, Shen P, Yu B, Xu X, Ge R, Cheng X, Chen Q, Bian J, Li Z, Wang J.
Eur J Med Chem · review; journal article · DOI 10.1016/j.ejmech.2020.112155Metabolism by Aldehyde Oxidase: Drug Design and Complementary Approaches to Challenges in Drug Discovery.
Manevski N, King L, Pitt WR, Lecomte F, Toselli F.
J Med Chem · review; journal article · DOI 10.1021/acs.jmedchem.9b00875The target landscape of clinical kinase drugs.
Klaeger S, Heinzlmeir S, Wilhelm M, Polzer H, Vick B, Koenig PA, Reinecke M, Ruprecht B, Petzoldt S, Meng C, Zecha J, Reiter K, Qiao H, Helm D, Koch H, Schoof M, Canevari G, Casale E, Depaolini SR, Feuchtinger A, Wu Z, Schmidt T, Rueckert L, Becker W, Huenges J, Garz AK, Gohlke BO, Zolg DP, Kayser G, Vooder T, Preissner R, Hahne H, Tõnisson N, Kramer K, Götze K, Bassermann F, Schlegl J, Ehrlich HC, Aiche S, Walch A, Greif PA, Schneider S, Felder ER, Ruland J, Médard G, Jeremias I, Spiekermann K, Kuster B.
Science · research support, non-u.s. gov't; research-article; journal article · DOI 10.1126/science.aan4368Benzimidazole Derivatives as Potent JAK1-Selective Inhibitors.
Kim MK, Shin H, Park KS, Kim H, Park J, Kim K, Nam J, Choo H, Chong Y.
J Med Chem · research support, non-u.s. gov't; journal article · DOI 10.1021/acs.jmedchem.5b01263Development of Selective Covalent Janus Kinase 3 Inhibitors.
Tan L, Akahane K, McNally R, Reyskens KM, Ficarro SB, Liu S, Herter-Sprie GS, Koyama S, Pattison MJ, Labella K, Johannessen L, Akbay EA, Wong KK, Frank DA, Marto JA, Look TA, Arthur JS, Eck MJ, Gray NS.
J Med Chem · research support, non-u.s. gov't; research-article; journal article · DOI 10.1021/acs.jmedchem.5b00710Discovery and development of Janus kinase (JAK) inhibitors for inflammatory diseases.
Clark JD, Flanagan ME, Telliez JB.
J Med Chem · research support, non-u.s. gov't; review; journal article · DOI 10.1021/jm401490p